NeuroStar® Advanced Therapy Providers Offer Free TMS Consultations During National Depression Awareness Month
October 01 2020 - 8:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced that participating providers
of its NeuroStar® Advanced Therapy treatment for depression are
offering complimentary consultations during National Depression
Awareness Month. During October, more than 300 practices across the
country will be participating in the program, which is designed to
educate depression sufferers and their loved ones about NeuroStar
as an available, non-drug and non-invasive depression treatment
alternative.
Depression currently impacts more than 16.1 million adults in
the U.S.,1,2,3 but many do not seek treatment or are not
helped by antidepressant medications. Antidepressant medications
are often the first treatment patients turn to, but the reality is
they aren’t a one-size-fits-all solution. There are currently 5.5
million adults with depression in the U.S. who do not see relief
from antidepressant medications.1,2,3 These startling
statistics, coupled with the unfortunate reality that the ongoing
COVID-19 pandemic has tripled the depression rate among adults in
the U.S.,4 make the need for open dialogue and education about
depression treatments more important than ever before. The Centers
for Disease Control and Prevention (CDC) identifies mental health
treatment as essential during the COVID-19 pandemic, and the
Clinical TMS Society recognizes TMS as an essential treatment for
patients during this time as well.5 NeuroStar, the market leader in
TMS, appreciates the critical role providers play in prioritizing
and maintaining mental health.
NeuroStar is a non-invasive treatment for adults with Major
Depressive Disorder (MDD) that uses magnetic pulses to stimulate
areas of the brain that are underactive in
depression.6,7 Neuronetics has more than 1,000 NeuroStar
devices installed in doctors’ offices and hospitals in the U.S.,
and many of these NeuroStar practices remain open and are offering
services during the pandemic, including free TMS consultations in
October and beyond, to make sure mental health needs are met and
potentially life-saving conversations continue.
“Over the past few months, we’ve seen the depression rate rise
along with patients in need. The pandemic has brought mental health
conversations to the forefront, and it is imperative that we
continue to educate patients about alternative treatment options
for depression,” said Keith J. Sullivan, President and CEO of
Neuronetics. “Reaching out to providers offering free consultations
is a critical first step patients can take. Our dedicated providers
offer not only information, but hope during each and every
consultation as they educate patients and their loved ones about
NeuroStar Advanced Therapy that may offer remission from
depression.”
During these consultations, patients have the opportunity to
learn more about NeuroStar from a healthcare professional and
collaborate with the provider to determine if NeuroStar Advanced
Therapy could be an appropriate next step for the treatment of
their depression. In addition to free consults, many providers also
offer free depression screenings. Visit NeuroStar’s Find a Doctor
page and call a local provider to learn more about available
services.
As part of its National Depression Awareness Month efforts,
Neuronetics is also hosting a webinar on October 7 in collaboration
with Mental Health America about mental health screening trends in
the time of COVID-19. October 8 is National Depression Screening
Day. Registration information is available here.
To join the conversation during National Depression Awareness
Month and to help destigmatize depression, follow NeuroStar on
Facebook, Instagram and Twitter, and access additional
resources at www.NeuroStar.com/DepressionAwareness. For more
information about NeuroStar, visit www.NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. (or the “Company”) is a commercial-stage medical
technology company focused on designing, developing, and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders. Its first commercial product is a
transcranial magnetic stimulation (TMS) device called the
NeuroStar® Advanced Therapy System. Additional information can be
found at www.neuronetics.com.
About NeuroStar® Advanced TherapyNeuroStar®
Advanced Therapy is the market leader in transcranial magnetic
stimulation (TMS), a non-invasive form of neuromodulation, and the
#1 choice of TMS doctors for patients with Major Depressive
Disorder (MDD). Widely available across the United
States, NeuroStar is reimbursed by most commercial and government
health plans, including Medicare and Tricare.
In the U.S., NeuroStar is indicated for the treatment of
MDD in adult patients who have failed to receive satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed
under Japan's national health insurance.
In an NIMH-funded, independent, randomized controlled trial,
patients treated with TMS using a clinical-trial version of the
NeuroStar System were 4.2 times more likely to achieve remission
compared to patients receiving sham treatment (P = 0.02; odds
ratio = 4.05).8 The most common side effect is pain or
discomfort at or near the treatment site, which usually resolves
within one week. It is contraindicated in people with non-removable
conductive metal in or near the head.
NeuroStar® is a registered trademark of Neuronetics,
Inc. (NASDAQ: STIM). For more information and full safety and
prescribing information, visit www.neurostar.com.
Media Contact:Meagan
DominickVault
Communications610-455-2779mdominick@vaultcommunications.com
1 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml,
accessed 1/16/20182 Kessler RC, et al. (2003), JAMA3 Gaynes BN, et
al. (2008), Cleveland Clinic Journal of Medicine4 Ettman CK, et al.
(2020) JAMA Network Open5 Clinical TMS Society. (2020).
Transcranial Magnetic Stimulation is an Essential Treatment [press
release].6 Post A, et al. (2001), J Psychiatric Research7 Liston C,
et al. (2014), Biol Psychiatry8 George MS, et al. (2010), Arch Gen
Psychiatry
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2023 to Apr 2024